• Stabilized the business and re-established consistent, procedure-driven demand
• Improved operating execution through focused commercial strategy and cost discipline
• Secured 10-year BARDA deal, delivering recurring readiness revenue and strengthening U.S. burn preparedness

AVITA Medical's Q1 2026 earnings presentation highlighted the company's progress in stabilizing the business and re-establishing consistent, procedure-driven demand. The actions taken over the past two quarters have translated into improved operating execution through a focused commercial strategy and cost discipline. Q1 2026 marks a transition to more consistent and predictable performance for the company. AVITA delivered a solid start to the year, reaffirming its 2026 net revenue guidance of $80 to $85 million, representing 12% to 19% growth over 2025. Key highlights include securing a 10-year BARDA deal (up to $25.5M, with $3.8M guaranteed), which will deliver recurring readiness revenue and strengthen U.S. burn preparedness. The company also presented compelling Cohealyx clinical data, showing a ~20-day faster grafting time compared to control dermal matrices, supporting strong clinical and adoption potential. Additionally, RECELL GO was cleared in Australia and New Zealand, unlocking new commercial markets. The company's Q1 2026 financial performance reflected the momentum from 2025, with improving year-over-year and sequential quarterly trends in revenue, gross profit margin, operating expenses, and net loss.

AVITA Medical reaffirmed its 2026 net revenue guidance of $80 to $85 million, representing 12% to 19% growth over 2025.